GBIM:OTCMKTS
GlobeImmune Inc
$0,00010
0,00%
(0,00) 1G
29 Eyl, 15:48:52 GMT-4 · USD
search
Tüm semboller
| Sembol | Fiyat | Değişiklik | Değişiklik % |
|---|
insights_autoGBIM ile ilgili en önemli analizler oluşturuluyor...
Piy. değ.
580,00
Ort. hacim
1,74 B
İşlem Hacmi
0,00
52 haftalık en yüksek
$0,04
52 haftalık en düşük
$0,00
Tedavüldeki hisse senedi sayısı
5,75 Mn
Çalışan sayısı
22
Piy. değ.
580,00
Ort. hacim
1,74 B
İşlem Hacmi
0,00
52 haftalık en yüksek
$0,04
52 haftalık en düşük
$0,00
Tedavüldeki hisse senedi sayısı
5,75 Mn
Çalışan sayısı
22
Haberler
Web kaynaklarından ve haber iş ortaklarından
Local 3 News
·
1 saat önce
RAW: NYSE: OPENING BELL (WEDNESDAY)
Seeking Alpha
·
1 saat önce
Stocks typically weaken ahead of midterms, then rebound, but resilience has persisted – analyst
MarketBeat
·
5 dakika önce
Bending Spoons (NASDAQ:BSP) Shares Gap Up - Time to Buy?
Yahoo Finance
·
1 saat önce
This ETF Has Crushed the S&P 500 in 2026. Here's Why I Think It Still Has Room to Grow.
Profil
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
GlobeImmune Inc hakkında
CEO-
Çalışan Sayısı22
Kuruluş Tarihi1 Oca 1995
Genel MerkezLouisville, Colorado, Amerika Birleşik Devletleri
Sektör-
Web Sitesiglobeimmune.com